Brief: Paratek Pharmaceuticals Announces Enrollment Of First Patient In Phase 2B Study Evaluating Nuzyra For Nontuberculous Mycobacterial Pulmonary Disease Caused By Mycobacterium Abscessus Complex
18/10/2021 21:49
Oct 18 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST
PATIENT IN
PHASE 2B STUDY EVALUATING NUZYRA® (OMADACYCLINE) FOR
NONTUBERCULOUS MYCOBACTERIAL (NTM) PULMONARY DISEASE CAUSED BY
MYCOBACTERIUM ABSCESSUS COMPLEX (MABC)
Source text for Eikon: ID:nGNX7bHhJj
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million